t(8;21)型急性髓系白血病发病机制新进展  

Recent advances in the pathogenesis of t(8;21)acute myeloid leukemia

作　　者：刘钰 王建祥 邱少伟 LIU Yu;WANG Jianxiang;QIU Shaowei(State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood DiseasesHospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin,300020,China;Tianjin Institutes of Health Science)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津300020 [2]天津医学健康研究院

出　　处：《临床血液学杂志》2025年第3期171-177,共7页Journal of Clinical Hematology

基　　金：中国医学科学院创新工程(No:2024-I2M-TS-023);天津市自然基金面上项目(No:23JCYBJC01050)。

摘　　要：t(8;21)型急性髓系白血病(AML)是AML中常见的细胞遗传学亚型,以AML1基因和ETO基因重排产生AML1-ETO融合基因为基本特征。近年来,随着该领域基础及临床探索的不断深入,t(8;21)型AML在基因调控、白血病细胞表型特征、协同基因突变、临床异质性等方面的研究均取得新的突破。文章拟就t(8;21)型AML发病机制新进展进行阐述,为临床治疗提供新思路。t(8;21)acute myeloid leukemia(AML)is a common cytogenetic subtype of AML,which is characterized by the rearrangement of the AML1gene and the ETO gene and the formation of the AML1-ETO fusion gene.Recent advances in both basic and clinical research have significantly enhanced our understanding of the mechanisms associated with t(8;21)AML,including the gene regulation,phenotypic characteristics of leukemia cells,the presence of secondary cytogenetic mutations,and the clinical heterogeneity observed in patients.This article reviews the latest developments in the pathogenesis of t(8;21)AML,aiming to provide valuable insights into clinical treatment strategies.

关 键 词：t(8 21)型急性髓系白血病 基因调控 细胞特征 二次突变 

分 类 号：R733.7[医药卫生—肿瘤]